---
title: The Prevention of Thromboembolic Complications Associated With Coil Embolization
nct_id: NCT05512546
overall_status: COMPLETED
sponsor: Muhammad Hassan
study_type: OBSERVATIONAL
primary_condition: Thromboembolic Stroke
countries: Pakistan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05512546.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05512546"
ct_last_update_post_date: 2022-08-23
last_seen_at: "2026-05-12T06:14:52.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Prevention of Thromboembolic Complications Associated With Coil Embolization

**Official Title:** Coil Embolization and Thromboembolic Complications in Patients With Ruptured Aneurysms

**NCT ID:** [NCT05512546](https://clinicaltrials.gov/study/NCT05512546)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Muhammad Hassan
- **Conditions:** Thromboembolic Stroke, Aspirin, Clopidogrel, Coil Embolization, Prevention
- **Start Date:** 2017-02-10
- **Completion Date:** 2020-12-10
- **CT.gov Last Update:** 2022-08-23

## Brief Summary

Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* All the patients enrolled in the study underwent MRI and Angiography.
* Participants included in the study were confirmed on assessment, and verified for ruptured aneurysm by imaging using either computed tomography (CT) or MRI.

Exclusion Criteria:

* Patients with any history of sensitivity or reaction to aspirin, or any contraindication for MRI, were excluded from the study.
```

## Arms

- **Aspirin Group** — patients were prescribed 75 mg/day of either aspirin for 6 months
- **Clopidogrel Group** — 75mg/day prescribed for 6 months

## Interventions

- **Aspir-Low Pill** (DRUG) — patients were prescribed 75 mg/day of either aspirin

## Primary Outcomes

- **High Intensity Areas** _(time frame: at 24 hours)_ — post procedural
- **High Intensity Areas** _(time frame: 3 months)_ — Post Procedural

## Secondary Outcomes

- **High Intensity Areas** _(time frame: at 6 months)_

## Locations (1)

- Umair Rasheed, Lahore, Punjab Province, Pakistan

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `locations.umair rasheed|lahore|punjab province|pakistan` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05512546.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05512546*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*